Most companies treat patent litigation like a rounding error: Settle and move on.
But the real question isnt whether you settleits whether settlement is becoming your default strategy when the math actually favors a smarter outcome.
In drug patents, th…

A new patent can feel like progressuntil its just a better disguise.
Heres the uncomfortable truth behind whats increasingly being called the salt change trap. In the world of pharma IP, a single tweakoften nothing more than switching the salt form o…

Pediatric exclusivity was supposed to be a shield.
Instead, in 2026 it increasingly looks like a liabilityan expensive, administratively heavy delay mechanism that rewards planning complexity more than therapeutic urgency.
Thats the core argument in a …

Bausch Health vs. Sun Pharma isnt just another patent headline. Its a case study in how generic entry debates are increasingly decided long before any courtroom verdictthrough claim construction, evidence timing, and the narrow window in which both sid…

Exelixis vs. Intas: The Patent Battle Behind Your Next Oral Cancer Pill
Patent litigation rarely makes headlines for longbut when it does, its usually because the stakes are high enough to reshape access, timelines, and valuation across an entire thera…

Big Pharmas next proxy war isnt about moleculesits about leverage.
If you track patent litigation, you already know the script: one company alleges infringement, another argues invalidity, and a court ultimately decides who gets the right to commercial…

Exelixis v. Handa: The Supreme Lesson for PharmaPatent Wins Still Depend on Procedure, Not Just Patents
Pharma litigation is often discussed like its purely about who has the better patent. But the real world lesson from Exelixis, Inc. v. Handa Pharmac…

If youre leading R&D, BD, or IP strategy in pharma, pay attention: the Takeda v. Sun decision isnt just a legal footnoteits a live signal about how the industry should think about patent scope, enforcement risk, and the real timeline of generic ent…